Select Page

What is MEN?

Photo capture: Endocrine (gland) system of the human body

Multiple Endocrine Neoplasia (MEN) disorders are inherited syndromes— this means they can be passed down in families. MEN disorders cause more than one gland of the endocrine (gland) system to develop neuroendocrine tumors, both benign (not cancer) and cancerous. The affected glands then over-produce hormones (the body’s chemical messengers), which in turn cause a variety of different symptoms. Each tumor may occur alone and independently of MEN. Early diagnosis and treatment are essential to help reduce the impact of these conditions on the patient.

MEN type 1

In MEN1, tumors may develop in the parathyroid glands in the neck, pituitary gland in the head and the pancreas in the abdomen.


MEN type 2

There are 3 distinct subtypes of MEN2:

MEN2A may present with tumors of the thyroid and parathyroid glands in the neck, and the adrenal glands near the kidneys;

MEN2B may present with tumors of the thyroid and adrenal glands, and throughout the gut. In addition, patients with MEN2B may have long fingers and toes and an unusual distinctive facial
appearance. MEN2B may also be referred to as MEN3.

FMTC (Familial MTC) presents only with hereditary cancer of the thyroid gland and is now considered a milder form of MEN2A.

Although most of the tumors in MEN2 are benign (not cancer), the thyroid tumors are always cancerous (medullary thyroid cancer), and can occur in early childhood. For this reason, surgery to remove the thyroid gland is usually necessary at an early age in children who have been identified as having MEN2. In addition, the adrenal tumors (pheochromocytomas) often produce too much adrenal gland hormones, which can raise blood pressure and lead to strokes and early death if left untreated.

How is MEN Diagnosed?

A diagnosis of MEN is made when either:
• A patient has 2 or more tumors common to MEN, or
• A patient has only 1 tumor but a family history of MEN A patient may have the gene change that causes MEN but not yet have developed any of the tumors. This person may be called a “MEN carrier” and should be offered regular tests and follow-up appointments at a center of expertise in the same way as a patient who already has MEN tumors. In many people (although not all) the gene change may be identified by genetic testing, but this should only be done after specialist genetic counselling.

For more information visit the AMEND website